CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer

Open Access
Publisher Website
Google Scholar
Abstract
No abstract available
Funding Information
  • NIH (R01 CA090687)
  • Research Supplement to Promote Diversity in Health-Related Research
  • Dana-Farber Specialized Program of Research Excellence (SPORE) in Breast Cancer (P50 CA168504)
  • SPORE Diversity Career Development Award
  • Susan G. Komen Investigator Initiated Research (IIR12223953)
  • Dana-Farber Claudia Adams Barr Award
  • National Health and Medical Research Council of Australia Fellowship
  • Instituto de Salud Carlos III (PI12/02606)
  • Asociación Española Contra el Cáncer
  • Deutsche Forschungsgemeinschaft (GE 976/9-1)